Rapid Communication
Copyright ©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Apr 7, 2008; 14(13): 2049-2054
Published online Apr 7, 2008. doi: 10.3748/wjg.14.2049
Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers
Hatsushi Yamagishi, Tomoyuki Koike, Shuichi Ohara, Toru Horii, Ryousuke Kikuchi, Shigeyuki Kobayashi, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Kaori Suzuki, Takanori Hishinuma, Junichi Goto, Tooru Shimosegawa
Hatsushi Yamagishi, Tomoyuki Koike, Shuichi Ohara, Toru Horii, Ryousuke Kikuchi, Shigeyuki Kobayashi, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Tooru Shimosegawa, Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryou-Machi, Aobaku, Sendai 9808574, Japan
Kaori Suzuki, Junichi Goto, Division of Clinical Pharmacy, Tohoku University Graduate School of Pharmaceutical Sciences, 1-1 Seiryou-Machi, Aobaku, Sendai 9808574, Japan
Takanori Hishinuma, Division of Pharmacotherapy, Tohoku University Graduate School of Pharmaceutical Sciences; Department of Pharmaceutical Sciences, Tohoku University Hospital, 1-1 Seiryou-Machi, Aobaku, Sendai 9808574, Japan
Author contributions: Yamagishi H, Koike T and Ohara S designed the research; Yamagishi H, Koike T, Ohara S, Horii T, Kikuchi R, Kobayashi S, Abe Y, Iijima K, Imatani A, Suzuki K, Hishinuma T, Goto J and Shimosegawa T performed the research; Yamagishi H, Koike T, Ohara S, Suzuki K and Hishinuma T analyzed the data; Yamagishi H, Koike T and Ohara S wrote the paper.
Correspondence to: Hatsushi Yamagishi, MD, Division of Gastroenterology Tohoku University graduate school of medicine, 1-1 Seiryou-Machi, Aobaku, Sendai 9808574, Japan. hatsushi@f2.dion.ne.jp
Telephone: +81-22-7177171
Fax: +81-22-7177177
Received: October 15, 2007
Revised: November 12, 2007
Published online: April 7, 2008
Abstract

AIM: To compare rabeprazole (RPZ; 10 mg) with Lansoprazole orally disintegrating tablets (LPZ; 30 mg OD) in terms of antisecretory activity and blood drug concentration after a single dose.

METHODS: Eight H pylori-negative cytochrome P450 (CYP) 2C19 extensive metabolizers were assigned to receive a single oral dose of RPZ 10 mg or LPZ 30 mg OD. Twelve hour intragastric pH monitoring was performed on the day of treatment. Blood samples were also collected after the administration of each drug.

RESULTS: LPZ 30 mg OD induced a significantly earlier rise in blood drug concentration than RPZ 10 mg; consequently, LPZ 30 mg OD induced a significantly earlier rise in median pH in the third and fourth hours of the study.

CONCLUSION: In H pylori-negative CYP2C19 extensive metabolizers, LPZ 30 mg OD induced a significantly faster inhibition of gastric acid secretion than RPZ 10 mg.

Keywords: LPZ 30 mg orally disintegrating tablets, Intragastric pH, Blood drug concentration, Cytochrome P450 2C19 extensive metabolizers, H pylori-negative